Provided by Tiger Fintech (Singapore) Pte. Ltd.

United Therapeutics

304.81
+12.164.16%
Post-market: 304.810.00000.00%18:37 EDT
Volume:1.14M
Turnover:346.76M
Market Cap:13.79B
PE:11.89
High:307.49
Open:292.02
Low:291.22
Close:292.65
Loading ...

United Therapeutics Q2 Revenue USD 798.6 Million Vs. IBES Estimate USD 804.3 Million

Reuters
·
30 Jul

Earnings Flash (UTHR) United Therapeutics Posts Q2 EPS $6.41, vs. FactSet Est of $6.94

MT Newswires Live
·
30 Jul

United Therapeutics Q2 2025 EPS $6.41 Misses $7.14 Estimate, Sales $798.600M Miss $805.482M Estimate

Benzinga
·
30 Jul

United Therapeutics Corporation Reports 12% Increase in Q2 2025 Revenues to $798.6 Million, Net Income Rises 11%

Reuters
·
30 Jul

United Therapeutics Corp - Authorizes $1 Bln Share Repurchase

THOMSON REUTERS
·
30 Jul

United Therapeutics Q2 Net Income USD 309.5 Million

THOMSON REUTERS
·
30 Jul

Liquidia's Yutrepia Drug Launch Expectations 'Overly Optimistic,' Oppenheimer Says

MT Newswires Live
·
29 Jul

United Therapeutics’ Promising IPF Treatment Study: A Market Game-Changer?

TIPRANKS
·
29 Jul

EVP & General Counsel Paul A. Mahon Reports Disposal of Common Shares of United Therapeutics Corporation

Reuters
·
26 Jul

United Therapeutics (UTHR) Receives a Buy from J.P. Morgan

TIPRANKS
·
17 Jul

United Therapeutics Corporation to Report Second Quarter 2025 Financial Results

Reuters
·
16 Jul

Paul A. Mahon, EVP & General Counsel, Reports Disposal of United Therapeutics Common Shares

Reuters
·
15 Jul

United Therapeutics Offers Favorable Profile Ahead of Key Data, Oppenheimer Says

MT Newswires Live
·
14 Jul

Oppenheimer bullish on United Therapeutics, sees grand upside from TETON readout

TIPRANKS
·
14 Jul

Renaissance Technologies: Inside the Machine of Quantitative Mastery

TradingKey
·
11 Jul

United Therapeutics Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
11 Jul

United Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
08 Jul

J.P. Morgan Sticks to Their Buy Rating for United Therapeutics (UTHR)

TIPRANKS
·
08 Jul

United Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
01 Jul

United Therapeutics' Tyvaso to Benefit from Q2 Seasonality, UBS Says

MT Newswires Live
·
30 Jun